151 related articles for article (PubMed ID: 25201618)
1. Prostate cancer: androgen suppression duration and zoledronic acid: under the RADAR.
Hutchinson L
Nat Rev Urol; 2014 Nov; 11(11):599. PubMed ID: 25201618
[No Abstract] [Full Text] [Related]
2. Prostate cancer: Androgen suppression duration and zoledronic acid: under the RADAR.
Hutchinson L
Nat Rev Clin Oncol; 2014 Oct; 11(10):559. PubMed ID: 25200412
[No Abstract] [Full Text] [Related]
3. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
4. Role of bisphosphonates in non-metastatic prostate cancer.
Saad F
Lancet Oncol; 2014 Sep; 15(10):1041-2. PubMed ID: 25130993
[No Abstract] [Full Text] [Related]
5. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
[TBL] [Abstract][Full Text] [Related]
6. The opportunity cost of androgen suppression in locally advanced prostate cancer.
Gray PJ; Efstathiou JA; Shipley WU
Asian J Androl; 2013 May; 15(3):356-7. PubMed ID: 23435474
[No Abstract] [Full Text] [Related]
7. Harms versus benefits with duration of androgen suppression.
Nguyen PL
Lancet Oncol; 2012 Dec; 13(12):1182-3. PubMed ID: 23151430
[No Abstract] [Full Text] [Related]
8. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
9. Re: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
Pitts WR
J Urol; 2003 Dec; 170(6 Pt 1):2392-3; author reply 2393-4. PubMed ID: 14634434
[No Abstract] [Full Text] [Related]
10. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
[TBL] [Abstract][Full Text] [Related]
11. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
Smith MR; Eastham J; Gleason DM; Shasha D; Tchekmedyian S; Zinner N
J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
[TBL] [Abstract][Full Text] [Related]
12. Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial.
Denham JW; Steigler A; Joseph D; Lamb DS; Spry NA; Duchesne G; Atkinson C; Matthews J; Turner S; Kenny L; Tai KH; Gogna NK; Gill S; Tan H; Kearvell R; Murray J; Ebert M; Haworth A; Kennedy A; Delahunt B; Oldmeadow C; Holliday EG; Attia J
Radiother Oncol; 2015 Jun; 115(3):301-7. PubMed ID: 26072289
[TBL] [Abstract][Full Text] [Related]
13. The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.
Campbell SC; Bhoopalam N; Moritz TE; Pandya M; Iyer P; Vanveldhuizen P; Ellis NK; Thottapurathu L; Garewal H; Warren SR; Friedman N; Reda DJ
Urology; 2010 May; 75(5):1138-43. PubMed ID: 20303574
[TBL] [Abstract][Full Text] [Related]
14. Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer.
Denham JW; Nowitz M; Joseph D; Duchesne G; Spry NA; Lamb DS; Matthews J; Turner S; Atkinson C; Tai KH; Gogna NK; Kenny L; Diamond T; Smart R; Rowan D; Moscato P; Vimieiro R; Woodfield R; Lynch K; Delahunt B; Murray J; D'Este C; McElduff P; Steigler A; Kautto A; Ball J
BJU Int; 2014 Sep; 114(3):344-53. PubMed ID: 24512527
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).
Smith MR; Halabi S; Ryan CJ; Hussain A; Vogelzang N; Stadler W; Hauke RJ; Monk JP; Saylor P; Bhoopalam N; Saad F; Sanford B; Kelly WK; Morris M; Small EJ
J Clin Oncol; 2014 Apr; 32(11):1143-50. PubMed ID: 24590644
[TBL] [Abstract][Full Text] [Related]
16. [Expert consensus for the diagnosis and treatment of bone metastasis from prostate cancer].
Expert Group on the Diagnosis and Treatment of Bone Metastasis from Prostate Cancer
Zhonghua Zhong Liu Za Zhi; 2010 May; 32(5):396-8. PubMed ID: 20723442
[No Abstract] [Full Text] [Related]
17. RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients.
Kachnic LA; Pugh SL; Tai P; Smith M; Gore E; Shah AB; Martin AG; Kim HE; Nabid A; Lawton CA
Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):382-6. PubMed ID: 24080992
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic guidelines in prostate cancer and role for bisphosphonates in bone metastasis].
Miki T; Okihara K
Nihon Rinsho; 2007 Nov; 65 Suppl 9():632-5. PubMed ID: 18161177
[No Abstract] [Full Text] [Related]
19. Editorial comment.
Tan WW
Urology; 2010 May; 75(5):1143. PubMed ID: 20451736
[No Abstract] [Full Text] [Related]
20. Long term zoledronic acid during androgen blockade for prostate cancer.
Casey R; Gesztesi Z; Rochford J
Can J Urol; 2010 Jun; 17(3):5170-7. PubMed ID: 20566009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
